https://orcid.org/0000-0003-3314-2411
References
- Ulrich R, Friend SH. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat Rev Drug Discov 2002;1:84–8.
- Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009;14:162–7.
- Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005;4:35–44.
- Llorens O, Perez JJ, Villar HO. Toward the design of chemical libraries for mass screening biased against mutagenic compounds. J Med Chem 2001;44:2793–804.
- Pritchard JF, Jurima-Romet M, Reimer ML, et al. Making better drugs: decision gates in non-clinical drug development. Nat Rev Drug Discov 2003;2:542–53.
- Lee HY, Inselman AL, Kanungo J, Hansen DK. Alternative models in developmental toxicology. Syst Biol Reprod Med 2012;58:10–22.
- Cassar S, Adatto I, Freeman JL, et al. Use of zebrafish in drug discovery toxicology. Chem Res Toxicol 2020;33:95–118.
- Spitsbergen JM, Kent ML. The state of the art of the zebrafish model for toxicology and toxicologic pathology research-advantages and current limitations. Toxicol Pathol 2003;31:62–87.
- Hill AJ, Teraoka H, Heideman W, Peterson RE. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol Sci 2005;86:6–19.
- Aspatwar A, Hammaren M, Koskinen S, et al. β-CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. J Enzyme Inhib Med Chem 2017;32:832–40.
- Aspatwar A, Hammaren MM, Parikka M, Parkkila S. Rapid evaluation of toxicity of chemical compounds using zebrafish embryos. J Visual Exp 2019;e59315:1–8.
- Aspatwar A, Hammaren M, Parikka M, et al. In vitro inhibition of Mycobacterium tuberculosis β-carbonic anhydrase 3 with Mono- and dithiocarbamates and evaluation of their toxicity using zebrafish developing embryos. J Enzyme Inhib Med Chem 2020;35:65–71.
- Aspatwar A, Parvathaneni NK, Barker H, et al. Design, synthesis, in vitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series. J Enzyme Inhib Med Chem 2020;35:109–17.
- Kazokaitė J, Aspatwar A, Kairys V, et al. Fluorinated benzenesulfonamide anticancer inhibitors of carbonic anhydrase IX exhibit lower toxic effects on zebrafish embryonic development than ethoxzolamide. Drug Chem Toxicol 2017;40: 309–19.
- Kari G, Rodeck U, Dicker AP. Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther 2007;82:70–80.
- MacRae CA, Peterson RT. Zebrafish-based small molecule discovery. Chem Biol 2003;10:901–8.
- Strahle U, Scholz S, Geisler R, et al. Zebrafish embryos as an alternative to animal experiments-a commentary on the definition of the onset of protected life stages in animal welfare regulations. Reprod Toxicol 2012;33:128–32.
- Goldsmith P. Zebrafish as a pharmacological tool: the how, why and when. Curr Opin Pharmacol 2004;4:504–12.
- Parng C, Seng WL, Semino C, McGrath P. Zebrafish: a preclinical model for drug screening. Assay Drug Dev Technol 2002;1:41–8.
- Spitsbergen JM, Tsai HW, Reddy A, et al. Neoplasia in zebrafish (Danio rerio) treated with 7,12-dimethylbenz[a]anthracene by two exposure routes at different developmental stages. Toxicol Pathol 2000;28:705–15.
- Levin ED, Chrysanthis E, Yacisin K, Linney E. Chlorpyrifos exposure of developing zebrafish: effects on survival and long-term effects on response latency and spatial discrimination. Neurotoxicol Teratol 2003;25:51–7.
- Di Fiore A, De Simone G, Alterio V, et al. The anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies. Org Biomol Chem 2016;14:4853–8.
- Carta F, Vullo D, Maresca A, et al. New chemotypes acting as isozyme-selective carbonic anhydrase inhibitors with low affinity for the offtarget cytosolic isoform II. Bioorg Med Chem Lett 2012;22:2182–5.
- D’Ambrosio K, Smaine FZ, Carta F, et al. Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups. J Med Chem 2012;55:6776–83.
- Carta F, Maresca A, Scozzafava A, Supuran CT. 5- and 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2012;22:267–70.
- Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.
- Akgul O, Di Cesare Mannelli L, Vullo D, et al. Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis. J Med Chem 2018;61:4961–77.
- Berrino E, Bua S, Mori M, et al. Novel sulfamide-containing compounds as selective carbonic anhydrase I inhibitors. Molecules 2017;22:1049.
- Bua S, Lucarini L, Micheli L, et al. Bioisosteric development of multitarget nonsteroidal anti-inflammatory drug-carbonic anhydrases inhibitor hybrids for the management of rheumatoid arthritis. J Med Chem 2020;63:2325–42.
- Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
- Gourmelon A, Delrue N. Validation in support of internationally harmonised OECD test guidelines for assessing the safety of chemicals. Adv Exp Med Biol 2016;856:9–32.
- Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. 2015;10:e0146021.
- Gillis EP, Eastman KJ, Hill MD, et al. Applications of fluorine in medicinal chemistry. J Med Chem 2015;58:8315–59.
- Aspatwar A, Becker HM, Parvathaneni NK, et al. Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in Xenopus oocytes. J Enzyme Inhib Med Chem 2018;33:1064–73.